Adjuvant therapy for breast cancer: Practical lessons from the early breast cancer trialists' collaborative group

Breast Disease

Volumn 21, Issue , 2004, Pages 3-13

  Hudis, Clifford A ^a   Dang, Chau T ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; THIOTEPA; TRASTUZUMAB;

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; COOPERATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FOLLOW UP; GENE OVEREXPRESSION; HEART DISEASE; HUMAN; INDIVIDUALIZATION; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; META ANALYSIS; OVARIECTOMY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 12444340932     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2004-21102     Document Type: Article

References (59)

1. Early Breast Cancer Trialists' Collaborative Group: Treatment of early breast cancer, vol. 1: Worldwide evidence 1985-1990. Oxford?: Oxford University Press, 1990.
2. Early Breast Cancer Trialists' Collaborative Group: Systematic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy? 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women, Lancet 339 (1992), 1-15, 71-85.
3. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview f the randomized trials, Lancet 352 (1998), 930 942.
4. Early Breast Cancer Trialists' Collaborative Group: Analysis overview results. Presented at the Fifth Meeting of the Early Breast Cancer Trialists Collaborative Group, Oxford, United Kingdom, September 21-23, 2000 abstract.
5. Tamoxifen for early breast cancer: An overview of the randomised trials, Early Breast Cancer Trialists' Collaborative Group, Lancet 351 (1998), 1451-1467.
6. Ovarian ablation in early breast cancer: Overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group, Lancet 348 (1996), 1189-1196.
7. W.A. Woodward, E.A. Strom, S.L. Tucker et al., Changes in the 2003 American Joint Committee on Cancer Staging for breast cancer dramatically affect stage-specific survival, J Clin Oncol 21 (2003), 3244-3248.
8. F. Cardoso, Microarray technology and its effect on breast cancer classification and prediction of outcome, Breast Cancer Res 5 (2003), 303 304.
9. S.H. Giordano, A.U. Buzdar, T.L. Smith et al., Is breast cancer survival improving? Cancer 100 (2004), 44-52.
10. G.T. Beatson, On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases, Lancet ii (1896), 104-107.
11. F. Boccardo, A. Rubagotti, D. Amoroso et al., Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial, J Clin Oncol 18 (2000), 2718-2727.
12. P. Schmid, M. Untch, D. Wallwiener et al., Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprolide acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: Pre-liminary results ofthe TABLE-study (Takeda Adjuvant Breast cancer study with Leuprolide Acetate), Anticancer Res 22 (2002), 2325-2332.
13. R. Jakesz, H. Hausmaninger and H. Samonigg, Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer, Eur J Cancer 38 (2002), 327-332.
14. M. Baum, A.U. Buzdar, J. Cuzick et al., Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomized trial, Lancet 359 (2002), 2131-2139.
15. P.E. Goss, J.N. Ingle, S. Martino et al., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N Engl J Med 349 (2003), 1793-1802.
16. H.E. Skipper, Kinetics of mammary tumor cell growth and implications for therapy, Cancer 28 (1971), 1479-1499.
17. B. Fisher, A.M. Brown, N.V Dimitrov, R. Poisson et al., Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15, J Clin Oncol 8 (1990), 1483-1496.
18. L. Hutchins, S. Green, P. Ravdin, D. Lew, S. Martino, M. Abeloff, A. Lyss, C. Henderson, C. Allred, S. Dakhil, I. Pierce, W. Goodwin, J. Caton, S. Rivkin, R. Chapman and K. Osbome, CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of intergroup trial INT 0102, Proc Am Soc Clin Oncol 17(1a) (1998), (abstr 2).
19. M.N. Levine, V.H. Bramwell, K.I. Pritchard et al., Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer, J Clin Oncol 16(8) (1998), 2651-2658.
20. P.P. DiFiore, J.H. Pierce, H.J. Kraus et al., erb B-2 is a potent oncogene when overexpressed in NIH-3T3 cells, Science 237 (1987), 178-182.
21. R.M. Hudziak, J. Schlessinger and A. Ullrich, Increased expression of the putative growth factor receptor p185HER causes transformation and tumorigenesis of NIH-3T3 cells, Proc Natl Acad Sci USA 84 (1987), 7159 7163.
22. M. Campiglio, G. Somenzi, C. Olgiati et al., Role of proliferation in HER2 status predicted response to doxorubicin, Int J Cancer 105 (2003), 568-573.
23. S. Paik, J. Bryant, C. Park et al., erb B-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer, J Natl Cancer Inst 90 (1998), 1361-1370.
24. A.D. Thor, D.A. Berry, D.R. Budman et al., erb B-2, p-53, and efficacy of adjuvant therapy in lymph node-positive breast cancer, J Natl Cancer Inst 90 (1998), 1346-1360.
25. A. Moliterni, S. Menard, P. Valagussa et al., HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer, J Clin Oncol 21 (2003), 458-462.
26. D.D. Von Hoff, G.M. Clark, G.R. Weiss et al., Use of in vitro dose-response effect to select antineoplastics for high-dose or regional administration regimens, J Clin Oncol 4 (1986), 1827-1834.
27. The Scandinavian Breast Cancer Study Group 9401. Results from a randomised adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy, Proc Am Soc Clin Oncol 18 2a) (1999), (abstr).
28. G.N. Hortobagyi, A.U. Buzdar, R.L. Theriault et al., Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma, J Natl Cancer Inst 92 (2000), 225 233.
29. W.P. Peters, G. Rosner, J. Vredenburgh et al., Updated results of a prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/NCIC Ma-13, Proc Am Soc Clin Oncol 20(21a) (2001), (abstr 81).
30. J.P. Crown, M. Lind, A. Gould et al., High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) induction in patients (pts) with breast cancer (BC) and 4 or more involved axillary lymph nodes (4+LN): The Anglo-Celtic I study, Proc Am Soc Clin Oncol 21(42a) (2002), (abstr 166).
31. H.H. Roche, P. Pouillart, N. Meyer et al., Adjuvant high dose chemotherapy (HDC) improves early outcome for high risk (>7) breast cancer patients: The Pegase 01 trial, Proc Am Soc Clin Oncol 20 26a) (2001), (abstr).
32. M.S. Tallman, R. Gray, N.J. Robert et al., Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer, N Engl J Med 349 (2003), 17-26.
33. S. Rodenhuis, M. Bontenbal, L. Beex et al., High-dose chemotherapy with hematopoetic stem-cell rescue for high-risk breast cancer, N Engl J Med 349 (2003), 7-16.
34. I.C. Henderson, D.A. Berry, G.D. Demetri et al., Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer, J Clin Oncol 21 (2003), 976-983.
35. E.P. Mamounas, J. Bryant, B.C. Lembersky et al., Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP-B 28, Proc Am Soc Clin Oncol 22(4a) (2003), (abstr 12).
36. B. Fisher, S. Anderson, D.L. Wickerham et al., Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22, J Clin Oncol 15 (1997), 1858-1869.
37. B. Fisher, S. Anderson, A. DeCillis et al., Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25, J Clin Oncol 17 (1999), 3374-3388.
38. L. Norton and R. Simon, Tumor size, sensitivity to therapy, and design of treatment schedules, Cancer Treat Rep 61 (1977), 1307-1317.
39. G. Bonadonna, M. Zambette and P. Valagussa, Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes, JAMA 273 (1995), 542-547.
40. C. Haskell, S. Green, G. Sledge et al., Phase III comparison of adjuvant high-dose doxorubicin plus cyclophosphamide (AC) versus sequential doxorubicin followed by cyclophosphamide (A→C) in breast cancer patients with 0-3 positive nodes (intergroup 0137), Proc. Am Soc. Clin. Onc 21 (2002), p. abstract 142.
41. M.L. Citron, D.A. Berry, C. Cirrincione et al., Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as post-operative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741, J Clin Oncol 21 (2003), 1431-1439.
42. C. Bernard-Marty, F. Cardoso and M.J. Piccart, Use and abuse of taxanes in the management of metastatic breast cancer, Eur J Cancer 39 (2003), 1978-1989.
43. M. Levin, The role of taxanes in breast cancer treatment, Drugs Today 37 (2001), 57-65.
44. C. Hudis, Adjuvant use of taxanes for patients with breast cancer: We see the tip of the iceberg, Clin Breast Cancer 3 (2002), 326-332.
45. M. Martin, T. Pienkowski, J. Mackey et al., TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients, BCIRG 001: 55 months follow-up, San Antonio Breast Cancer Symposium (2003), (abstr 43).
46. G.N. Hortobagyi, Treatment of breast cancer, N Engl J Med 339 (1998), 974-984.
47. P.P. Rosen, S. Groshen, P.E. Saigo et al., Pathologic prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years, J Clin Oncol 7 (1989), 1239-1251.
48. E.G. Mansour, P.M. Ravdin and L. Dressler, Prognostic factors in early breast carcinoma, Cancer 74 (1994), 381-400.
49. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ull-rich and W.L. McGuire, Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235 (1987), 177-182.
50. M.D. Pegram, G.Pauletti and D.J. Slamon, HER-2/neu as a predictive marker of response to breast cancer therapy, Breast Cancer Res Treat 51 (1998), 65-77.
51. M. Fornier, M. Risio, Van Poznak et al., HER2 testing and correlation with efficacy of trastuzumab therapy, Oncology 16 (2003), 1340-1348, 1351-1352.
52. J. Baselga, A.D. Seidman, P.P. Rosen et al., HER2 overexpression and paclitaxel sensitivity in breast cancer therapeutic implications, Oncology 11 (1997), 43-48.
53. S. Paik, S. Shak, G. Tang et al., Multi-gene RT-PCR assay for predicting recurrence in node-negative breast cancer patients: NSABP studies B-20 and B-14, San Antonio Breast Cancer Symposium (2003), (abstr 16).
54. D.J. Slamon, B. Leyland-Jones, S. Shak et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med 344 (2001), 783-792.
55. I.J. Diel, E.F. Solomayer and G. Bastert, Treatment of metastatic bone disease in breast cancer, Clin Breast Cancer 1 (2000), 43-51.
56. I.J. Diel, E.F. Solomayer, S.D. Costa et al., Reduction in new metastases in breast cancer with adjuvant clodronate treatment, N Engl J Med 339 (1998), 357-363.
57. T. Powles, S. Paterson, J.A. Kanis et al., Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer, J Clin Oncol 20, 3219-3224.
58. B.K. Dunn and L.G. Ford, From adjuvant therapy to breast cancer prevention: BCPT and STAR, Breast J 7 (2001), 144-157.
59. B. Fisher, J. Dignam, N. Wolmark et al., Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer, J Natl Cancer Inst 89 (1997), 1673-1682.